Heroin Information References
Bowersox, J.A. Buprenorphine may soon be heroin treatment option. NIDA
NOTES 10:8-9, 1995.
Bowersox, J.A. Heroin update: smoking, injecting cause similar effects; usage
patterns may be shifting. NIDA NOTES 10:8-9, 1995.
Cooper, J.R.; Altman, F.; Brown, B.S.; and Czechowicz, D., eds. Research in the
Treatment of Narcotic Addiction: State of the Art. National Institute on Drug
Abuse Monograph, DHHS Pub. # (ADM) 83-1281, 1983.
Dole, V.P.; Nyswander, M.E.; and Kreek, M.J. Narcotic blockade. Arch Intern
Med 118:304-309, 1966.
Goldstein, A. Heroin addiction: Neurology, pharmacology, and policy. J
Psychoactive Drugs 23(2):123-133, 1991.
Hughes, P.H., and Rieche, O. Heroin epidemics revisited. Epidemiol
Rev 17(1):63-73, 1995.
Kornetsky, C. Action of opioid on the brain-reward system. In: Rapaka, R.S.,
and Sorer, H., eds. Discovery of Novel Opioid Medications. National Institute
on Drug Abuse Research Monograph 147. NIH Pub. No. 95- 3887. Washington, DC:
Supt. of Docs., U.S. Govt. Print Off., 1991, pp. 32-52.
Kreek, M.J. Rationale for maintenance pharmacotherapy of opiate dependence.
In: O'Brien, C.P., and Jaffe, J.H., eds. Addictive States. New York: Raven
Press, 1992, pp. 205-230.
Kreek, M.J. Using methadone effectively: achieving goals by application of
laboratory, clinical, and evaluation research and by development of innovative
programs. In: Pickens, R.; Leukefeld, C.; and Schuster, C.R., eds. Improving
Drug Abuse Treatment. National Institute on Drug Abuse Research Monograph 106.
Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 245-266, 1991.
Lewis, J.W., and Walter, D. Buprenorphine: background to its development as a
treatment for opiate dependence. In Blaine, J.D., ed. Buprenorphine: An
Alternative for Opiate Dependence. National Institute on Drug Abuse Research
Monograph 121. DHSS Pub. No. (ADM) 92-1912. Washington, DC: Supt. of Docs.,
U.S. Govt. Print. Off., 1992, pp. 5-11.
Mathias, R. NIDA survey provides first national data on drug abuse during
pregnancy. NIDA NOTES 10:6-7, 1995.
National Institute on Drug Abuse. Epidemiologic Trends in Drug Abuse: Vol. 1.
Highlights and Executive Summary, Community Epidemiology Work Group. NIH Pub.
No. 00-4739. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 2000.
National Institute on Drug Abuse. "Heroin." NIDA Capsule. NIDA, 1986.
National Institute on Drug Abuse. IDUs and infectious diseases. NIDA NOTES 9:15, 1994.
National Institute on Drug Abuse. National Survey Results on Drug Use From the
Monitoring the Future Study, 1975-1998, Vol. I: Secondary School Students.
Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1999.
National Institute on Drug Abuse. National Survey Results on Drug Use From the
Monitoring the Future Study, 1975-1994, Vol. II: College Students and Young
Adults. NIH Pub. No. 96-4027. Washington, DC: Supt. of Docs., U.S. Govt. Print.
Off., 1995.
Novick, D.M.; Richman, B.L.; Friedman, J.M.; Friedman, J.E.; Fried, C.; Wilson,
J.P.; Townley, A.; and Kreek, M.J. The medical status of methadone maintained
patients in treatment for 11-18 years. Drug and Alcohol Depend 33:235-245, 1993.
Office of National Drug Control Policy. Drugs and Crime Data: Heroin Facts and
Figures. Rockville, MD: U.S. Department of Justice, 1996.
Sobel, K. NIDA's AIDS projects succeed in reaching drug addicts, changing
high-risk behaviors. NIDA NOTES 6:25-27, 1991.
Substance Abuse and Mental Health Services Administration. Preliminary
Estimates of Drug Related Emergency Department Episodes: Advance Report
Number 17. Rockville, MD: SAMHSA, 1996.
Substance Abuse and Mental Health Services Administration. Preliminary Results
from the 1996 National Household Survey on Drug Abuse. SAMHSA, 1997.
Swan, N. Research demonstrates long-term benefits of methadone treatment.
NIDA NOTES 9:1, 4-5, 1994.
Swan, N. Treatment practitioners learn about LAAM. NIDA NOTES 9:5, 1994.
Woods, J.H.; France, C.P.; and Winger, G.D. Behavioral pharmacology of
buprenorphine: issues relevant to its potential in treating drug abuse.
In: Blain, J.D., ed. Buprenorphine: An Alternative for Opiate Dependence.
National Institute on Drug Abuse Research Monograph 121. DHHS Pub. No.
(ADM) 92-1912. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off.,1992,
pp. 12-27.
Methamphetamine Information References
"Blood Level of Intravenous Drug Users," by R.L. Norton, B.T.
Burton, and J. McGirr. Journal of Clinical Toxicology 34(4):425-30, 1996.
Epidemiologic Trends in Drug Abuse: Vol. I. Highlights and
Executive Summary of the Community Epidemiology Work Group,
June 2001. NIH Pub. No. 01-4916A. National Institute on Drug
Abuse, 2001.
Epidemiologic Trends in Drug Abuse: Vol. II. Proceedings of the
Community Epidemiology Work Group, June 2001. NIH Pub.
No. 01-4917A. National Institute on Drug Abuse, 2001.
"Integrating Treatments for Methamphetamine Abuse: A Psychosocial
Perspective," by A. Huber, W. Ling, S. Shoptaw, V. Gulati, P.
Brethen, and R. Rawson. Journal of Addictive Diseases, 16(4):41-50, 1997.
"Like Methamphetamine, Ecstacy May Cause Long-Term Brain Damage,"
by R. Mathias. NIDA NOTES 11:7, 1996.
Methamphetamine Abuse (NIDA Capsules). National Institute on
Drug Abuse, September 1997.
National Methamphetamine Strategy. U.S. Department of
Justice, 1996.
National Survey Results on Drug Use From the Monitoring the
Future Study, 1975-1994, Vol. I: Secondary School Students. NIH Pub.
No. 93-3498. National Institute on Drug Abuse, 1995.
National Survey Results on Drug Use From the Monitoring the Future
Study, 1975-1994, Vol. II: College Students and Young Adults. NIH Pub.
No. 96-4027. National Institute on Drug Abuse, 1995.
"NIDA Survey Provides First National Data on Drug Abuse During
Pregnancy," by R. Mathias. NIDA NOTES 10:6-7, 1995.
Summary of Findings from the 2000 National Household Survey on Drug
Abuse. Substance Abuse and Mental Health Services Administration, 2000.
Detailed Emergency Department Tables 2000, Drug Abuse Warning
Network. Substance Abuse and Mental Health Services Administration,
available online at www.samhsa.gov/oas/dawn.htm.
Cocaine Information References
Gold, Mark S. Cocaine (and Crack): Clinical Aspects (181-198), Substance Abuse:
A Comprehensive Textbook, Third Edition, Lowinson, ed. Baltimore, MD: Williams &
Wilkins, 1997.
Harvey, John A. and Kosofsky, Barry, eds. Cocaine: Effects on the Developing Brain.
Annals of the New York Academy of Sciences, Volume 846, 1998.
National Institute on Drug Abuse. Epidemiologic Trends in Drug Abuse: Vol. 1.
Highlights and Executive Summary of the Community Epidemiology Work Group. NIH Pub.
No. 98-4207. Washington, DC: Supt. of Docs., U.S. Govt. Print. Off., 1997.
National Institute on Drug Abuse. NIDA Infofax, Crack and Cocaine, 1998.
National Institute on Drug Abuse. National Survey Results on Drug Use From the
Monitoring the Future Survey, 1998.
Office of National Drug Control Policy. The National Drug Control Strategy, 1998:
A Ten Year Plan.
Snyder, Solomon H. Drugs and the Brain (122-130). New York: Scientific American
Library, 1996.
Substance Abuse and Mental Health Services Administration. Preliminary Results from
the 1997 National Household Survey on Drug Abuse. SAMHSA, 1998.
Marijuana Information References
Johnston, L.D.; O'Malley, P.M.; and Bachman, J.G. Monitoring the Future; National Results on Adolescent Drug Use, Overview and Key findings, 2000. NIH Pub. No. 01-4923. Bethesda, MD: NIDA, NIH, DHHS, 2000.
Substance Abuse and Mental Health Services Administration. Summary of Findings from the 1999 National Household Survey on Drug Abuse. DHHS Pub. No. (SMA) 00-3466. Rockville, MD: DHHS, 2000.
ElSohly, M.A., and Ross, S.A. Quarterly report: Potency monitoring project. November 2004, unpublished.
Tashkin, D.P. Pulmonary complications of smoked substance abuse. West J Med 152:525-530, 1990.
Sarafian, T.A.; Magallanes, J.A.; Shau, H.; Tashkin, D.; and Roth, M.D. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am J Respir Cell Mol Biol 20(6):1286-1293, 1999.
Roth, M.D.; Arora, A.; Barsky, S.H.; Kleerup, E.C.; Simmons, M.; and Tashkin, D.P. Airway inflammation in young marijuana and tobacco smokers. Am. J. Respir Crit Care Med 157:928-937, 1998.
Heishman, S.J.; Arasteh, K; and Stitzer, M.L. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav 58:97-101, 1997.
Fletcher, J.M.; Page, J.B.; Francis, D.J.; Copeland, K.; Naus, M.J.; Davis, C.M.; Morris, R.; Krauskopf, D.; and Santz, P. Cognitive correlates of chronic cannabis use in Costa Rican men. Archives of General Psychiatry 53:1051-1057, 1996.
Block, R.I., and Ghoneim, M.M. Effects of chronic marijuana use on human cognition. Psychopharmacology 100(1-2): 219-228, 1993.
Graham, A.W.; Schultz, T.K.; and Wilford, B.B. (eds.). Principles of Addiction Medicine, 2nd Edition. Chevy Chase, MD: American Society of Addiction Medicine, Inc., 1998.
Ameri, A. The effects of cannabinoids on the brain. Prog Neurobiol 58(4):315-348, 1999.
Patrick, G., and Struve, F.A. Reduction of auditory P50 gating response in marihuana users: further supporting data. Clin Electroencephalogr 31(2):88-93, 2000.
Jones, R.T., et al. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21(8-9 Suppl):143S-152S, 1981.
Srivistava, M.D.; Srivastava, B.I.; and Brouhard, B. Delta-9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40(3):179-185, 1998.
Zhu, L.X.; Stolina, M.; Sharma, S.; Gardner, B.; Roth, M.D.; Tashkin, D.P.; and Dubinett, S.M. Delta-9 tetrahydrocannabinol inhibits antitumor immunity by a CB-2 receptor-mediated, cytokine dependent-pathway. J Immunology 165(1):373-380, 2000.
Gilman, A.G.; Rall, T.W.; Nies, A.S.; and Taylor, P. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Edition. New York: Pergamon Press, 1998.
Adams, I.B., and Martin, B.R. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 91:1585-1614, 1996.
Zhang, Z.-F.; Morgenstern, H.; Spitz, M.R.; Tashkin, D.P.; Yu, G.-P.; Marshall, J.R.; Hsu, T.C; and Stimson, P.S. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiology, Biomarkers & Prevention 6:1071-1078, 1999.
Brook, J.S., et al. The effect of early marijuana use on later anxiety and depressive symptoms. NYS Psychologist January:35-39, 2001.
Green, B.E., and Ritter, C. Marijuana use and depression. J Health Soc Behav 41(1):40-49, 2000.
Wilson, W.; Mathew, R.; Turkington, T.; Hawk, T.; Coleman, R.E.; and Provenzale, J. Brain morphological changes and early marijuana use: A magnetic resonance and positron emission tomography study. J Addict Dis 19(1):1-22, 2000.
Brook, J.S.; Balka, E.B.; and Whiteman, M. The risks for late adolescence of early adolescent marijuana use. Am J Public Health 89(10):1549-1554, 1999.
Community Epidemiology Work Group. Epidemiologic Trends in Drug Abuse, June 2000. Vol. 1, Highlights and Executive Summary. NIH Pub. No. 00-4739A. Bethesda, MD: NIDA, NIH, DHHS, 2000.
ElSohly, M.A.; Ross, S.A.; Mehmedic, Z.; Arafat, R.; Yi, B.; and Banahan, B. Potency trends of delta-9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of Forensic Sciences 45(1):24-30, 2000.
Office of Applied Studies. Results from the 2001 National Household Survey on Drug Abuse: Volume II. Technical Appendices and Selected Data Tables. NHSDA Series H-18. DHHS Pub. No. (SMA) 02-3759. Rockville, MD: SAMHSA, 2004.
Johnston, L.D.; O'Malley, P.M.; and Bachman, J.G. Monitoring the Future: National Survey Results on Drug Use, 1975-2001. Volume I: Secondary School Students. NIH Pub. No. 02-5106. Bethesda, MD: NIDA, NIH, DHHS, 2004.
Office of Applied Studies. Year-end 2000 Emergency Department Data from the Drug Abuse Warning Network (Table 24). DAWN Series D-18; DHHS Pub. No. (SMA) 01-3532. Rockville, MD: SAMHSA, 2001.
National Institute of Justice, Arrestee Drug Abuse Monitoring Program. 1999 Annual Report on Drug Use Among Adult and Juvenile Arrestees. Washington, DC: U.S. Department of Justice, June 2000.
Herkenham, M.; Lynn, A.; Little, M.D.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; and Rice K.C. Cannabinoid receptor localization in the brain. Proc Natl Acad Sci, USA. 87:1932-1936, 1990.
Ohlsson, A.; Lindgren, J.E.; Wahlen, A.; Agurell, S.; Hollister, L.E.; and Gillespie, H.K. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28(3):409-416, 1980.
Foltin, R.W.; Fischman, M.W; Pedroso, J.J.; and Pearlson, G.D. Marijuana and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behav 28(4):459-464,1987.
Chen, J.P.; Paredes, W.; Li, J.; Smith, D.; Lowinson, J.; and Gardner, E.L. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156-162, 1990.
French, E.D.; Dillon, K.; and Wu, X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neurosci Lett 226:159-162, 1997.
Leshner, A.I., and Koob, G.F. Drugs of abuse and the brain. Proc Assoc Amer Physicians 111:99-108, 1999.
Pope, H.G., and Yurgelun-Todd, D. The residual cognitive effects of heavy marijuana use in college students. JAMA 272(7):521-527, 1996.
Mason, A.P., and McBay, A.J. Ethanol, marijuana, and other drug use in 600 drivers killed in single-vehicle crashes in North Carolina, 1978Ð1981. J Forensic Sci 29(4):987-1026, 1984.
Williams, A.F.; Peat, M.A.; Crouch, D.J.; Wells, J.K.; and Finkle, B.S. Drugs in fatally injured young male drivers. Public Health Report 100:19-25, 1985.
Cimbura, G.; Lucas, D.M.; Bennett, R.C.; and Donelson, A.C. Incidence and toxicological aspects of cannabis and ethanol detected in 1,394 fatally injured drivers and pedestrians in Ontario (1982Ð1984). J Forensic Sci 35:1035-1041, 1990.
National Highway Traffic Safety Administration (NHSTA) Notes. Marijuana and alcohol combined severely impede driving performance. Annals of Emergency Medicine 35(4):398-399, 2000.
Ford, D.E.; Vu, H.T.; and Anthony, J.C. Marijuana use and cessation of tobacco smoking in adults from a community sample. Drug and Alcohol Dependence 67:243-248, 2004.
Polen, M.R; Sidney, S.; Tekawa, I.S.; Sadler. M.; and Friedman, G.D. Health care use by frequent marijuana smokers who do not smoke tobacco. West J Med 158:596-601, 1993.
Sridhar, K.S.; Raub, W.A.; Weatherby, N.L., Jr.; Metsch, L.R.; Surratt, H.L.; Inciardi, J.A.; Duncan, R.C.; Anwyl, R.S.; and McCoy, C.B. Possible role of marijuana smoking as a carcinogen in the development of lung cancer at a young age. Journal of Psychoactive Drugs 26(3):285-288, 1994.
Hoffman, D.; Brunnemann, K.D.; Gori, G.B.; and Wynder, E.E.L. On the carcinogenicity of marijuana smoke. In: V.C. Runeckles, ed., Recent Advances in Phytochemistry. New York: Plenum, 1975.
Cohen, S. Adverse effects of marijuana: Selected issues. Annals of the New York Academy of Sciences 362:119-124, 1981.
Klein, T.W.; Newton, C.; and Friedman, H. Resistance to Legionella pneumophila suppressed by the marijuana component, tetrahydrocannabinol. Journal of Infectious Disease 169:1177-1179, 1994.
Mittleman, M.A.; Lewis, R.A.; Maclure, M.; Sherwood, J.B.; and Muller, J.E. Triggering myocardial infarction by marijuana. Circulation 103:2805-2809, 2001.
Lynskey. M., and Hall, W. The effects of adolescent cannabis use on educational attainment: A review. Addiction 95(11):1621-1630, 2000.
Kandel, D.B., and Davies, M. High school students who use crack and other drugs. Arch Gen Psychiatry 53(1):71-80, 1996.
Rob, M.; Reynolds, I.; and Finlayson, P.F. Adolescent marijuana use: Risk factors and implications. Aust NZ J Psychiatry 24(1):45-56, 1990.
Lehman, W.E., and Simpson, D.D. Employee substance abuse and on-the-job behaviors. Journal of Applied Psychology 77(3):309-321, 1992.
Brook, J.S.; Cohen, P.; and Brook, D.W. Longitudinal study of co-occurring psychiatric disorders and substance use. J Acad Child and Adolescent Psych 37:322-330, 1998.
Pope, H.G.; and Gruber, A.J.; Hudson, J.I.; Huestis, M.A.; and Yurgelun-Todd. D. Neuropsychological performance in long-term cannabis users. Archives of General Psychiatry. Arch Gen Psychiatry 58(10):909-915, 2001.
Scheier, L.M., and Botvin, G.J. Effects of early adolescent drug use on cognitive efficacy in early-late adolescence: A developmental structural model. Journal of Substance Abuse 7(4):397-404, 1996.
Lester, B.M., and Dreher, M. Effects of marijuana use during pregnancy on newborn cry. Child Development 60:764-771, 1989.
Fried, P.A. The Ottawa prenatal prospective study (OPPS): Methodological issues and findingsÑit's easy to throw the baby out with the bath water. Life Sciences 56:2159-2168, 1995.
Fried, P.A. Prenatal exposure to marihuana and tobacco during infancy, early and middle childhood: Effects and an attempt at synthesis. Arch Toxicol Suppl 17:233-60, 1995.
Office of Applied Studies. National and State Estimates of the Drug Abuse Treatment Gap: 2000 National Household Survey on Drug Abuse. NHSDA Series H-14. DHHS Pub. No. (SMA) 02-3640. Rockville, MD: SAMHSA, 2004.
Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS): 1994-1999, National Admissions to Substance abuse Treatment Services. DASIS Series: S-14, DHHS Pub. No. (SMA) 01-3550. Rockville, MD: DHHS, 2001.
Haney, M.; Ward, A.S.; Comer, S.D.; Foltin, R.W.; and Fischman, M.W. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395-404, 1999.
Budney, A.J.; Hughes, J.R.; Moore, B.A.; and Novy, P.L. Marijuana abstinence effects in marijuana smokers maintained in their environment. Arch Gen Psychiatry 58:917-924, 2001.
Kouri, E.M.; Pope, H.G.; and Lukas, S.E. Changes in aggressive behavior during withdrawal from long-term marijuana use. Psychopharmacology 143:302-308, 1999.
Steinberg, K.L.; Roffman, R.A.; Carroll, K.M.; Kabela, E.; Kadden, R.; Miller, M.; and Duresky, D. The Marijuana Treatment Project Research Group. Tailoring cannabis dependence treatment for a diverse population. Addiction 97(Suppl 1):135-142, 2004.
Stephens, R.S.; Roffman R.A.; and Curtin, L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 68(5):898-908, 2000.
Budney, A.J.; Higgins, S.T.; Radonovich, K.J.; and Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 68(6):1051-1061, 2000.
Heyser, C.J.; Hampson, R.E.; and Deadwyler, S.A. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task-specific firing of hippocampal cells. Journal of Pharmacology & Experimental Therapeutics 264(1):294-307, 1993.
Landfield, P.W.; Cadwallader, L.B.; and Vinsant, S. Quantitative changes in hippocampal structure following long exposure to delta-9-tetrahydrocannabinol: Possible mediation of glucocorticoid systems. Brain Res 443(1-2):47-62, 1988.
Walker, M.J.; Huang, S.M.; Strangman, N.M.; Tsou, K.; and Sanudo-Pena, M.C. Pain modulation by the release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences 96(21):12198-12203, 1999.
Wenger, T.; Toth, B.E.; Juaneda, C.; Leonardelli, J.; and Tramu, G. The effects of cannabinoids on the regulation of reproduction. Life Sci 65(6-7):695-701, 1999.
Lawston, J.; Borella, A.; Robinson, J.K.; and Whitaker-Azmitia, P.M. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55, 212-2. Brain Research 877:407-410, 2000.
Chan, G.C.K.; Hinds, T.R.; Impey, S.; and Storm, D.R. Hippocampal neurotoxicity of _-9-tetrahydrocannabinol. J Neuroscience 18(14):5322-5332, 1998.
Piomelli, D.; Giuffrida, A.; Calignano, A.; and Rodriguez de Fonseca, F. The endocannabinoid system as a target for therapeutic drugs. TIPS 21:218-224, 2000.
Halucinogens Information References
Abraham, H.D.; Aldridge, A.M.; and Gogia, P. The psychopharmacology of
hallucinogens. Neuropsychopharmacology 14: 285-298, 1996.
Aghajanian, G.K., and Marek, G.J. Serotonin and hallucinogens.
Neuropsychopharmacology 21: 16S-23S, 1999.
Backstrom, J.R.; Chang, M.S.; Chu, H.; Niswender, C.M.; and Sanders-Bush, E.
Agonist-directed signaling of serotonin 5-HT2c receptors: differences between
serotonin and lysergic acid diethylamide (LSD). Neuropsychopharmacology 21:
77S-81S, 1999.
Carroll, M.E. PCP and hallucinogens. Advances in Alcohol and Substance
Abuse 9(1-2): 167-190, 1990.
Christophersen, A.S. Amphetamine designer drugs: an overview and epidemiology.
Toxicology Letters 112-113: 127-131, 2000.
Frankenheim, J., and Lin, G.C. Hallucinogenic Drugs. In: Craighead, W.E., and
Nemeroff, C., eds. Encyclopedia of Psychology and Neuroscience. New York: John
Wiley & Sons, in press.
Hofmann, A. LSD: My Problem Child. New York: McGraw-Hill, 1980.
Javitt, D.C., and Zukin, S.R. Recent advances in the phencyclidine model of
schizophrenia. American Journal of Psychiatry 148:1301-1308, 1991.
Sanders-Bush, E. Neurochemical Evidence That Hallucinogenic Drugs are 5-HT2c
Receptor Agonists: What Next? In: Lin, G.C., and Glennon, R.A., eds.
Hallucinogens: An Update. National Institute on Drug Abuse Research Monograph
No. 146. NIH Pub. No. 94-3872. Washington, D.C.: U.S. Government Printing
Office, 1994.
Ungerleider, J.T., and Pechnick, R.N. Hallucinogens. In: Lowenstein, J.H.;
Ruiz, P.; and Millman, R.B., eds. Substance Abuse: A Comprehensive Textbook,
Second Edition. Baltimore: Williams & Wilkins, 1992
Inhalants Information References
Balster, R.L. Neural basis of inhalant abuse. Drug and Alcohol Dependence 51(1-2):207-214, 1998.
Bowen, S.E.; Wiley, J.L.; Evans, E.B.; Tokarz, M.E.; and Balster, R.L. Functional observational battery comparing effects of ethanol, 1,1,1-trichlorethane, ether, and flurothyl. Neurotoxicology and Teratology 18(5):577-585, 1996.
Edwards, R.W., and Oetting, E.R. Inhalant use in the United States. In: Kozel, N.; Sloboda, Z.; and De La Rosa, M. (eds.), Epidemiology of Inhalant Abuse: An International Perspective. National Institute on Drug Abuse Research Monograph 148. DHHS Publication No. NIH 95-3831. Washington, DC: U.S. Government Printing Office, 8-28, 1995.
Fendrich, M.; Mackesy-Amiti, M.E.; Wislar, J.S.; and Goldstein, P.J. Childhood abuse and the use of inhalants: Differences by degree of use. American Journal of Public Health 87(5):765-769, 1997.
Jones, H.E., and Balster, R.L. Inhalant abuse in pregnancy. Obstetrics and Gynecology Clinics of North America 25(1):153-167, 1997.
National Institute on Drug Abuse. National Survey Results on Drug Use From the Monitoring the Future Study, 1999 (www.monitoringthefuture.org).
National Institute on Drug Abuse. NIDA Infofax, Inhalants, 1999.
Riegel, A.C., and French, E.D. Acute toluene induces biphasic changes in rat spontaneous locomotor activity which are blocked by remoxipride. Pharmacology, Biochemistry and Behavior 62(3):399-402, 1999.
Sharp, C.W., and Rosenberg, N.L. Inhalants. In: Lowinson, J.H.; Ruiz, P.; Millman, R.B.; and Langrod, J.G. (eds.), Substance Abuse: A Comprehensive Textbook, 3d. ed. Baltimore: Williams and Wilkins, 246-264, 1996.
Sharp, C.W., and Rosenberg, N. Inhalant-related disorders. In: Tasman, A.; Kay, J.; and Lieberman, J.A. (eds.), Psychiatry, Vol. 1. Philadelphia: W.B. Saunders, 835-852, 1997.
Substance Abuse and Mental Health Services Administration. Population Estimates From the 1998 National Household Survey on Drug Abuse. SAMHSA, 1999.
Substance Abuse and Mental Health Services Administration. Summary Findings From the 1998 National Household Survey on Drug Abuse. SAMHSA, 1999.
Soderberg, L.S. Immunomodulation by nitrite inhalants may predispose abusers to AIDS and Kaposi's sarcoma. Journal of Neuroimmunology 83(1-2):157-161, 1998.
Soderberg, L.S. Increased tumor growth in mice exposed to inhaled isobutyl nitrite. Toxicology Letters 101(1-2):35-41, 1999.
Woody, G.E.; Donnell, D,; Seage, G.R.; et al. Non-injection substance use correlates with risky sex among men having sex with men: Data from HIV/NET. Drug and Alcohol Dependence 53(3):197-205, 1999.279(6): 22-26, 1998.
|
